On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.
- How To Stand Up A Hospital-Based CAR-T Manufacturing Network
- September 2026 — CDMO Opportunities And Threats Report
- An Incomplete Response: Will The FDA Finish What It Started With Real-Time CRLs?
- Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty
- Is Your Supply Chain Ready For The End Of Class VI?
- Demonstrating Gene Therapy Potency: A Strategic Road Map
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
- When Lyophilization Fails At Scale, First Scrutinize Your Formulation
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Sterile Filter Membrane Selection For Cell Culture Media Filtration
Membrane design and filtration capacity affect pressure, throughput, and scale-up. See how comparative testing reveals opportunities to reduce required filtration area, capsule use, and changeouts.
-
High-Performing Ionizable Lipids For Controlled Nucleic Acid Delivery
Ionizable lipids are central to effective mRNA delivery, influencing potency, biodistribution, and toxicity. See why advancing delivery beyond the liver will require stronger structure-function insights.
-
Fully Automated Cell Culture Passaging And Expansion
Automating cell culture tasks can reduce human error and free scientists from labor-intensive routines. Discover how imaging and automated systems enhance accuracy and reproducibility in cell culture processes.
-
Future-Proofing Life Sciences Manufacturing: 2025 CDMO Trends
Review contract manufacturing's evolution, driven by technological advancements and regulatory changes, and how CMOs and CDMOs are navigating opportunities and challenges.
-
Powering More Efficient Clinical Development With AI And ML
Explore how AI and ML are revolutionizing clinical trials by automating data processes to accelerate research and transform data into actionable outcomes for patient care.
-
Reducing Cost Drivers And Improving Efficiency In CAR T Cell Manufacturing
Fragmented CAR T cell manufacturing workflows drive up costs and extend timelines. This case study quantifies what consolidating manufacturing and QC through automation actually delivers.
-
Where Speed Meets Complexity In Bioprocess Development
Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.
-
Bringing Clinical Trials To Everyone's Backyard
Learn how bringing clinical trials to any community around the world is not only possible but also increases patient access and reach and improves recruitment and retention.
-
Separation Of cfDNA With An NGS Kit On Fragment Analyzer Systems
Learn how precise sizing methods reveal nucleosome patterns in cfDNA and help distinguish true signal from extraction‑related artifacts for more reliable genomic analysis.
-
What Is Size Exclusion Chromatography (SEC)?
Aggregation can compromise mAb quality at many stages of development. Learn why size exclusion chromatography is a trusted approach for detecting aggregates and supporting confident characterization.
NEWSLETTER ARCHIVE
- 11.02.26 -- Why Human-Relevant Models Are Reshaping Early Drug Discovery
- 11.02.26 -- How CGT Developers Should Think About Manufacturing Models, Hybrid Strategies, And Scale
- 10.30.26 -- What Regionalized Filtration Networks Mean For Biopharma
- 10.30.26 -- Why Clinical Trial Design Matters For MSC Success
- 10.29.26 -- Expert Insights On Choosing The Right CGT Manufacturing Model
- Earlier Decisions, Better Processes Required For Automating Autologous CAR T Manufacturing
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
- Inside The Next Phase In Autoimmune CAR T From Meeting On The Mesa 2026
- What LSPA's Life Sciences Future Says About The Road Ahead For CGT
- Inside Scaling Next-Gen MSCs Without Scaling Risk
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts
More Editorial Collections

